Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A1 | P04798 | 3/20 | 0.54 |
| ▸ | CYP1B1 | Q16678 | 3/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.52 |
| ▸ | TUBB1 | Q9H4B7 | 11/20 | 0.50 |
| ▸ | TUBB4A | P04350 | 8/20 | 0.50 |
| ▸ | TUBB | P07437 | 8/20 | 0.50 |
| ▸ | TUBA3C | P0DPH7 | 8/20 | 0.50 |
| ▸ | TUBA1B | P68363 | 8/20 | 0.50 |
| ▸ | TUBA4A | P68366 | 8/20 | 0.50 |
| ▸ | TUBB4B | P68371 | 8/20 | 0.50 |
| ▸ | TUBB3 | Q13509 | 8/20 | 0.50 |
| ▸ | TUBB2A | Q13885 | 8/20 | 0.50 |
| ▸ | TUBB8 | Q3ZCM7 | 8/20 | 0.50 |
| ▸ | TUBA3E | Q6PEY2 | 8/20 | 0.50 |
| ▸ | TUBA1A | Q71U36 | 8/20 | 0.50 |
| ▸ | TUBA1C | Q9BQE3 | 8/20 | 0.50 |
| ▸ | TUBB6 | Q9BUF5 | 8/20 | 0.50 |
| ▸ | TUBB2B | Q9BVA1 | 8/20 | 0.50 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.50 |
| ▸ | SLCO2B1 | O94956 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Oxi-4503 SCHEMBL12677563 | 1.00 | CYP1A1 (0.54) | CYP1A1CYP1B1CYP1A2TUBB1TUBB4A | |
| Oxi-4503 SCHEMBL30934510 | 0.99 | CYP1A1 (0.52) | CYP1A1CYP1B1CYP1A2TUBB1TUBB4A | |
| SCHEMBL14175308 | 0.97 | CYP1A1 (0.57) | CYP1A1CYP1B1CYP1A2TUBB1TUBB4A | |
| SCHEMBL14175295 | 0.97 | CYP1A1 (0.57) | CYP1A1CYP1B1CYP1A2TUBB1TUBB4A | |
| SCHEMBL14175305 | 0.90 | TUBB1 (0.51) | CYP1A1CYP1B1CYP1A2TUBB1TUBB4A | |
| SCHEMBL14175304 | 0.90 | TUBB1 (0.51) | CYP1A1CYP1B1CYP1A2TUBB1TUBB4A | |
| SCHEMBL14175316 | 0.88 | CYP1A1 (0.49) | CYP1A1CYP1B1CYP1A2TUBB1TUBB4A | |
| SCHEMBL14175307 | 0.88 | TUBB1 (0.50) | CYP1A1CYP1B1CYP1A2TUBB1TUBB4A | |
| SCHEMBL14175299 | 0.88 | TUBB1 (0.50) | CYP1A1CYP1B1CYP1A2TUBB1TUBB4A | |
| SCHEMBL13724720 | 0.88 | CYP1A1 (0.55) | CYP1A1CYP1B1CYP1A2TUBB1TUBB4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 408 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4313156-B1 | DISULFIDE-BASED PRODRUG COMPOUNDS | UNIV MUENCHEN LUDWIG MAXIMILIANS (DE) | 2025-08-06 | — | — | EP | claimed |
| US-20240207414-A1 | DISULFIDE-BASED PRODRUG COMPOUND | LUDWIG-MAXIMILIANS-UNIVERSITAT MUNCHEN (DE) | 2024-06-27 | — | — | US | claimed |
| US-20240156965-A1 | DICHALCOGENIDE PRODRUGS | LUDWIG-MAXIMILIANS-UNIVERSITAT MUNCHEN (DE) | 2024-05-16 | — | — | US | claimed |
| EP-4320124-A1 | DICHALCOGENIDE PRODRUGS | Ludwig-Maximilians-Universität München (DE) | 2024-02-14 | — | — | EP | claimed |
| EP-4313156-A1 | DISULFIDE-BASED PRODRUG COMPOUNDS | Ludwig-Maximilians-Universität München (DE) | 2024-02-07 | — | — | EP | claimed |
| US-20220401556-A1 | USE OF VDAS TO ENHANCE IMMUNOMODULATING THERAPIES AGAINST TUMORS | ONCOTELIC THERAPEUTICS, INC. | 2022-12-22 | — | — | US | claimed |
| WO-2022214598-A1 | DICHALCOGENIDE PRODRUGS | LUDWIG-MAXIMILIANS-UNIVERSITÄT MÜNCHEN (DE) | 2022-10-13 | — | — | WO | claimed |
| EP-4071148-A1 | DICHALCOGENIDE PRODRUGS | Ludwig-Maximilians-Universität München (DE) | 2022-10-12 | — | — | EP | claimed |
| WO-2022200347-A1 | DISULFIDE-BASED PRODRUG COMPOUNDS | LUDWIG-MAXIMILIANS-UNIVERSITÄT MÜNCHEN (DE) | 2022-09-29 | — | — | WO | claimed |
| EP-4062942-A1 | DISULFIDE-BASED PRODRUG COMPOUNDS | Ludwig-Maximilians-Universität München (DE) | 2022-09-28 | — | — | EP | claimed |
| US-11419934-B2 | Use of VDAS to enhance immunomodulating therapies against tumors | ONCOTELIC THERAPEUTICS, INC. (US) | 2022-08-23 | — | — | US | claimed |
| US-20260144799-A1 | COMPOSITION COMPRISING A FIRST RAS INHIBITOR, SECOND RAS INHIBITOR AND A SHP2 INHIBITOR FOR USE IN THE TREATMENT OF CANCER | Revolution Medicines, Inc. (US) | 2026-05-28 | — | — | US | disclosed |
| US-12636250-B2 | Microneedle array patches (MAPs), systems, and methods for manufacturing and using same | TERRESTRIAL BIO, INC. (US) | 2026-05-26 | — | — | US | disclosed |
| US-12637445-B2 | KIF18A inhibitors | AMGEN INC. (US) | 2026-05-26 | — | — | US | disclosed |
| US-20260139051-A1 | COMBINATION THERAPIES USING MOLECULES BINDING TO TCR | MARENGO THERAPEUTICS INC (US) | 2026-05-21 | — | — | US | disclosed |
| WO-2022047046-A1 | METHODS OF DETECTING TRBC1 OR TRBC2 | MARENGO THERAPEUTICS, INC. (US) | 2022-03-03 | — | — | WO | disclosed |
| US-20220064297-A1 | ANTI-TCR ANTIBODY MOLECULES AND USES THEREOF | MARENGO THERAPEUTICS, INC. | 2022-03-03 | — | — | US | disclosed |
| WO-2022046920-A2 | MULTIFUNCTIONAL MOLECULES THAT BIND TO CALRETICULIN AND USES THEREOF | MARENGO THERAPEUTICS, INC. (US) | 2022-03-03 | — | — | WO | disclosed |
| US-20220056015-A1 | KIF18A INHIBITORS | AMGEN INC. (US) | 2022-02-24 | — | — | US | disclosed |
| US-11236069-B2 | KIF18A inhibitors | AMGEN INC. (US) | 2022-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12636250-B2 | Microneedle array patches (MAPs), systems, and methods for manufacturing and using same | GLP1R, NPY1R, NPY4R | CYP1A1 2639/4885CYP1B1 2617/4885CYP1A2 2523/4885 |
| US-20220401556-A1 | USE OF VDAS TO ENHANCE IMMUNOMODULATING THERAPIES AGAINST TUMORS | CD274, PDCD1LG2, PDCD1 | CYP1A1 3411/4885CYP1B1 3624/4885CYP1A2 3828/4885 |
| US-12637445-B2 | KIF18A inhibitors | KIF18A, KIF18B, KIF2C | CYP1A1 3727/4885CYP1B1 3233/4885CYP1A2 3875/4885 |
| US-20260144799-A1 | COMPOSITION COMPRISING A FIRST RAS INHIBITOR, SECOND RAS INHIBITOR AND A SHP2 INHIBITOR FOR USE IN THE TREATMENT OF CANCER | PDCD1, CD274, PTPN1 | CYP1A1 3822/4885CYP1B1 3903/4885CYP1A2 4557/4885 |
| US-20240207414-A1 | DISULFIDE-BASED PRODRUG COMPOUND | CBS, MSR1, P4HB | CYP1A1 827/4885CYP1B1 656/4885CYP1A2 1247/4885 |
| US-20240156965-A1 | DICHALCOGENIDE PRODRUGS | DHCR7, DECR1, CYP27A1 | CYP1A1 593/4885CYP1B1 772/4885CYP1A2 714/4885 |
| US-20260139051-A1 | COMBINATION THERAPIES USING MOLECULES BINDING TO TCR | CD2, CD4, CD47 | CYP1A1 4242/4885CYP1B1 4536/4885CYP1A2 4551/4885 |
| US-11236069-B2 | KIF18A inhibitors | KIF18A, KIF18B, KIF15 | CYP1A1 2801/4885CYP1B1 2424/4885CYP1A2 2449/4885 |
| US-20220056015-A1 | KIF18A INHIBITORS | KIF18A, KIF18B, KIF15 | CYP1A1 3329/4885CYP1B1 2858/4885CYP1A2 2959/4885 |
| US-11419934-B2 | Use of VDAS to enhance immunomodulating therapies against tumors | CD274, PDCD1LG2, CA4 | CYP1A1 3326/4885CYP1B1 3655/4885CYP1A2 3725/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.